Advertisement
UK markets close in 7 hours 23 minutes
  • FTSE 100

    8,423.78
    +42.43 (+0.51%)
     
  • FTSE 250

    20,597.04
    +65.74 (+0.32%)
     
  • AIM

    785.57
    +1.87 (+0.24%)
     
  • GBP/EUR

    1.1621
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2528
    +0.0004 (+0.03%)
     
  • Bitcoin GBP

    50,293.72
    +1,335.04 (+2.73%)
     
  • CMC Crypto 200

    1,307.82
    -50.19 (-3.70%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • DOW

    39,387.76
    +331.36 (+0.85%)
     
  • CRUDE OIL

    79.85
    +0.59 (+0.74%)
     
  • GOLD FUTURES

    2,374.20
    +33.90 (+1.45%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,967.79
    +429.98 (+2.32%)
     
  • DAX

    18,790.35
    +103.75 (+0.56%)
     
  • CAC 40

    8,227.17
    +39.52 (+0.48%)
     

Global Psychedelic Drugs Market Analysis Report 2022 Featuring AstraZeneca, COMPASS, Klarisana, F. Hoffmann-La Roche, Takeda Pharma, Dr. Reddy's Laboratories, Pfizer, Merck & Co., & Lundbeck

Company Logo
Company Logo

Dublin, May 06, 2022 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market Size & Share to 2027" report has been added to ResearchAndMarkets.com's offering.

Increase in prevalence of depression across the globe is the key driving factor which is expected to boost the global psychedelic drugs market growth. Furthermore, change in lifestyle and requirement for enhanced and better life quality will positively contribute the market growth.

Also, increase in research and development activities is expected to propel the market growth during this analysis period. Moreover, increase in dependency on psychedelic drugs for treatment of depression is expected to propel the global psychedelic drugs market growth during this forecast period.

However, stringent rules and regulations imposed by government to commercialize psychedelic drugs is the major challenging factor which is expected to hinder the global psychedelic drugs market growth. Also, poor efficiency and safety profile of existing intervention will affect the market growth over the forecast period.

Key Questions Addressed by the Report

  • What are the Key Opportunities in Global Psychedelic Drugs Market?

  • What will be the growth rate from 2019 to 2027?

  • Which segment/region will have highest growth?

  • What are the factors that will impact/drive the Market?

  • What is the competitive Landscape in the Industry?

  • What is the role of key players in the value chain?

  • What are the strategies adopted by key players?

ADVERTISEMENT

Market Key Players

  • AstraZeneca

  • COMPASS

  • Klarisana

  • F. Hoffmann-La Roche Ltd

  • Takeda Pharmaceutical Company Limited

  • Dr. Reddy's Laboratories Ltd

  • Pfizer Inc

  • Merck & Co. Inc

  • Lundbeck A/S

Market Taxonomy

By Drug Type

  • Lysergic Acid Diethylamide (LSD)

  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)

  • Phencyclidine

  • Gamma Hydroxybutyric Acid (GHB)

  • Ketamine

  • Ayahuasca

  • Salvia

  • Psilocybin

  • Others

By Route of Administration

  • Oral

  • Injectable

  • Inhalation

By Distribution Channel

  • Direct Retailers

  • Online Pharmacies

  • Others

By End-User

  • Hospitals

  • Homecare

  • Specialty Clinics

  • Others

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Psychedelic Drugs Market Outlook

5 Global Psychedelic Drugs Market, By Drug Type

6 Global Psychedelic Drugs Market, By Route of Administration

7 Global Psychedelic Drugs Market, By Distribution Channel

8 Global Psychedelic Drugs Market, By End User

9 Global Psychedelic Drugs Market, By Region

For more information about this report visit https://www.researchandmarkets.com/r/45fp15

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900